At a glance
ClinicalIndex Comparison Record- ✓Age ≥18 years, either gender, any race
- ✓Positive history of ocular allergies with documented positive skin test reaction to seasonal (grasses, ragweed, trees) or perennial allergen (cat/dog dander, dust mites, cockroach) within past 24 months
- ✓Visual acuity ≥0.7 logMAR or better in each eye on ETDRS chart
- ✕Known contraindications or sensitivities to investigational product or its components
- ✕Ocular conditions that could affect safety or trial parameters: narrow angle glaucoma, clinically significant blepharitis, follicular conjunctivitis, iritis, pterygium, or dry eye
- ✕Ocular surgical intervention within 3 months prior to Visit 1 or during study; refractive surgery within past 6 months
- ✕History of retinal detachment, diabetic retinopathy, or active retinal disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
In Brief
A Phase 2 clinical trial evaluating ADX-102 Ophthalmic Drops (0.5%), ADX-102 Ophthalmic Drops (0.1%), and 1 other intervention for Conjunctivitis, Allergic. Completed, enrolled 154 participants across 5 sites.
Detailed Summary
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Phase 2b Evaluation of the Onset and Duration of ADX-102 Ophthalmic Drops (0.5% and 0.1%) Compared to Vehicle of ADX-102 Ophthalmic Drops in the Conjunctival Allergen Challenge (Ora-CAC®) Model of Acute Allergic Conjunctivitis.
Study Details
Timeline
Interventions
ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.
ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.
Vehicle of ADX-102 Ophthalmic Drops administered twice in two weeks.